Lowe Brockenbrough & Co. Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 150,063 shares of the biopharmaceutical company’s stock after purchasing an additional 1,952 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Pfizer were worth $5,507,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in PFE. Hudson Bay Capital Management LP grew its holdings in Pfizer by 2.2% in the 2nd quarter. Hudson Bay Capital Management LP now owns 230,000 shares of the biopharmaceutical company’s stock valued at $7,521,000 after buying an additional 5,000 shares in the last quarter. Argus Investors Counsel Inc. grew its holdings in Pfizer by 5.3% in the 2nd quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock valued at $3,547,000 after buying an additional 5,500 shares in the last quarter. Gilman Hill Asset Management LLC grew its holdings in Pfizer by 7.9% in the 3rd quarter. Gilman Hill Asset Management LLC now owns 123,183 shares of the biopharmaceutical company’s stock valued at $4,521,000 after buying an additional 9,021 shares in the last quarter. AE Wealth Management LLC grew its holdings in Pfizer by 35.0% in the 2nd quarter. AE Wealth Management LLC now owns 376,967 shares of the biopharmaceutical company’s stock valued at $12,327,000 after buying an additional 97,799 shares in the last quarter. Finally, Altium Wealth Management LLC grew its holdings in Pfizer by 2.5% in the 3rd quarter. Altium Wealth Management LLC now owns 73,130 shares of the biopharmaceutical company’s stock valued at $2,684,000 after buying an additional 1,758 shares in the last quarter. Institutional investors own 69.08% of the company’s stock.
In other Pfizer news, major shareholder Pfizer Inc bought 1,200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 27th. The stock was acquired at an average price of $10.00 per share, with a total value of $12,000,000.00. Following the completion of the purchase, the insider now directly owns 27,349,211 shares of the company’s stock, valued at approximately $273,492,110. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronald E. Blaylock bought 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $38.55 per share, with a total value of $501,150.00. Following the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at $154,200. The disclosure for this purchase can be found here. 0.08% of the stock is owned by company insiders.
A number of research analysts have commented on the company. Berenberg Bank assumed coverage on Pfizer in a report on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price objective on the stock. ValuEngine lowered Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating and set a $37.00 target price on the stock in a report on Thursday. UBS Group increased their target price on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Wednesday, July 29th. Finally, Mizuho reissued a “buy” rating and set a $43.00 target price on shares of Pfizer in a report on Tuesday, September 15th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus price target of $39.66.
Pfizer stock opened at $35.28 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $196.05 billion, a PE ratio of 14.00, a P/E/G ratio of 3.10 and a beta of 0.66. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97. The stock has a 50-day moving average price of $36.74 and a two-hundred day moving average price of $36.59.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.01. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company had revenue of $12.13 billion during the quarter, compared to the consensus estimate of $12.30 billion. During the same period last year, the company earned $0.75 earnings per share. The firm’s revenue was down 4.3% compared to the same quarter last year. As a group, analysts predict that Pfizer Inc. will post 2.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be given a dividend of $0.38 per share. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.31%. Pfizer’s dividend payout ratio (DPR) is 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.